Publications by authors named "M E Evangelopoulos"
In the past two decades, there has been a considerable increase of our knowledge with regards to the pathophysiology and management of various demyelinating diseases of the central nervous system [...
View Article and Find Full Text PDFArticle Synopsis
- HPV vaccines show promise in fighting HPV-related cancers, but clinical success has been challenging.
- Recent studies using spherical nucleic acids (SNAs) with a specific peptide (E7) and a CpG adjuvant demonstrated superior immune responses in humanized mice, particularly with distinctive oligonucleotide anchors.
- Stronger anchors improved T-cell responses and dendritic cell activation, emphasizing the importance of structural design for effective therapeutic vaccines.
Elicitation of effective antitumor immunity following cancer vaccination requires the selective activation of distinct effector cell populations and pathways. Here we report a therapeutic approach for generating potent T cell responses using a modular vaccination platform technology capable of inducing directed immune activation, termed the Protein-like Polymer (PLP). PLPs demonstrate increased proteolytic resistance, high uptake by antigen-presenting cells (APCs), and enhanced payload-specific T cell responses.
View Article and Find Full Text PDFAssociation of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
J Neurol Sci
June 2024
Introduction: Progressive multifocal leukoencephalopathy (PML) is a potentially life-threatening complication among Multiple Sclerosis (MS) patients under natalizumab treatment, with serum anti-JCV antibody titers being used for stratification risk. Given the critical role of interferon (IFN)/B-cell activating factor (BAFF) axis in humoral immune responses against viruses, we explored whether it is involved in the generation of serum anti-JCV antibodies among these patients.
Methods: 162 consecutive patients with relapsing-remitting MS under natalizumab treatment were included.
Introduction: Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 (cluster of differentiation) monoclonal antibodies (mAbs) such as ocrelizumab (OCR) and ofatumumab (OFA) show a reduction mainly of B-lymphocytes, but also other lymphocyte subsets can be affected by these treatments. There is limited data on differences between lymphocyte subset counts of pwMS after treatment initiation with OCR or OFA.
Objective: To compare lymphocyte subset counts after treatment initiation in pwMS treated with OCR and OFA.